Abstract
To the Editor:
In their article on the use of sunitinib in patients with pancreatic neuroendocrine tumors, Raymond et al. (Feb. 10 issue) report that they increased the daily dose of sunitinib to 50 mg in 10% of patients. We recently administered sunitinib (at a daily dose of 37.5 mg) to a 61-year-old man with a pancreatic neuroendocrine tumor and liver metastases. Plasma sunitinib concentrations are routinely monitored by liquid chromatography at each visit at our institution, which allows us to calculate the area under the curve (AUC) for sunitinib from a population pharmacokinetics model. After 2 months of treatment, . . .
In their article on the use of sunitinib in patients with pancreatic neuroendocrine tumors, Raymond et al. (Feb. 10 issue) report that they increased the daily dose of sunitinib to 50 mg in 10% of patients. We recently administered sunitinib (at a daily dose of 37.5 mg) to a 61-year-old man with a pancreatic neuroendocrine tumor and liver metastases. Plasma sunitinib concentrations are routinely monitored by liquid chromatography at each visit at our institution, which allows us to calculate the area under the curve (AUC) for sunitinib from a population pharmacokinetics model. After 2 months of treatment, . . .
| Original language | English |
|---|---|
| Pages (from-to) | 1873; author reply 1873-5 |
| Journal | The New England journal of medicine |
| Volume | 364 |
| Issue number | 19 |
| DOIs | |
| Publication status | Published - 12 May 2011 |
| Externally published | Yes |